Department of Orthopedics and Traumatology, Ministry of Health, Kayseri State Hospital, Kayseri, Turkey.
Department of Orthopedics and Traumatology, Faculty of Medicine, Medeniyet University, Istanbul, Turkey.
J Med Food. 2021 Nov;24(11):1230-1234. doi: 10.1089/jmf.2020.0143. Epub 2021 Mar 17.
Osteosarcoma has a poor prognosis and survival rate due to inadequate chemotherapy, high recurrence ability, high metastasis potential, and almost no radiotherapy being applied. One of the strategies to solve these problems is to develop the pharmacologically active plant metabolite, amygdalin, in combination therapeutic systems. In this project, the antiproliferative effects of amygdalin alone and in binary or ternary combinations with some anticancer drugs (cisplatin, 5-fluorouracil, oxaliplatin, and camptothecin), antiparasitic drugs (metronidazole and miltefosine), and an antigout drug (colchicine) were examined using human bone osteosarcoma cell lines (MG-63 and Saos2), the chondrosarcoma cell line (SW1353), and the normal human cell line (FL). Known half-maximal inhibitory concentration values of the drugs were taken into consideration, and the recommended combination ratios were used in the Chou-Talalay method. The strong synergistic effect commonly seen in the combination of amygdalin with miltefosine, metronidazole, camptothecin, colchicine, oxaliplatin, 5-fluorouracil, and cisplatin dual drug indicates that these combinations can be used in cancer treatment. The synergistic effect caused by amygdalin decreases toxicity by increasing drug yield. However, amygdalin antagonism seen in several combinations may prevent these pairs from being used together. In combination with antagonistic effects, it may be preferable to use amygdalin alone as it generally causes strong antiproliferative effects. Besides, there is a more potent synergism between amygdalin and triple drug combinations. Overall, these results emphasize that amygdalin combinations in treatment of bone cancer are significant.
成骨肉瘤由于化疗不足、高复发能力、高转移潜能和几乎不适用放疗，预后和生存率较差。解决这些问题的策略之一是开发具有药理活性的植物代谢产物苦杏仁苷，结合联合治疗系统。在这个项目中，单独使用苦杏仁苷以及与一些抗癌药物（顺铂、5-氟尿嘧啶、奥沙利铂和喜树碱）、抗寄生虫药物（甲硝唑和米替福新）和抗痛风药物（秋水仙碱）的二元或三元组合，对人骨肉瘤细胞系（MG-63 和 Saos2）、软骨肉瘤细胞系（SW1353）和正常人细胞系（FL）进行了抗增殖作用的检测。考虑到药物的已知半最大抑制浓度值，并在 Chou-Talalay 方法中使用了推荐的组合比例。苦杏仁苷与米替福新、甲硝唑、喜树碱、秋水仙碱、奥沙利铂、5-氟尿嘧啶和顺铂双重药物联合使用时通常会出现强烈的协同作用，这表明这些组合可用于癌症治疗。苦杏仁苷与药物的协同作用通过增加药物产量来降低毒性。然而，在几种组合中观察到的苦杏仁苷拮抗作用可能会阻止这些组合一起使用。考虑到拮抗作用，单独使用苦杏仁苷可能更可取，因为它通常会产生强烈的抗增殖作用。此外，苦杏仁苷与三联药物组合之间存在更强的增效作用。总的来说，这些结果强调了苦杏仁苷联合治疗骨癌的重要性。
